Hesperetin’s health potential: moving from preclinical to clinical evidence and bioavailability issues, to upcoming strategies to overcome current limitations
Bahare Salehi, Natália Martins, Monica Butnariu, Ioan Sărac, Iulia Cristina Bagiu, Shahira M. Ezzat, Jinfan Wang, Aaron Koay, Helen Sheridan, Charles Oluwaseun Adetunji, Prabhakar Semwal, Mauricio Schoebitz, Miquel Martorell, Javad Sharifi‐Rad
Abstract
Flavonoids are common in the plant kingdom and many of them have shown a wide spectrum of bioactive properties. Hesperetin (Hst), the aglycone form of hesperidin, is a great example, and is the most abundant flavonoid found in Citrus plants. This review aims to provide an overview on the in vitro, in vivo and clinical studies reporting the Hst pharmacological effects and to discuss the bioavailability-related issues. Preclinical studies have shown promising effects on cancer, cardiovascular diseases, carbohydrate dysregulation, bone health, and other pathologies. Clinical studies have supported the Hst promissory effects as cardioprotective and neuroprotective agent. However, further well-designed clinical trials are needed to address the other Hst effects observed in preclinical trials, as well as to a more in-depth understanding of its safety profile.